EAACI Congress 2025
BackTPS33 - Allergen immunotherapy 04
Saturday 14 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
Allergen-specific IgE/IgG4 ratio as biomarker of allergen immunotherapy efficacy in house dust mite-sensitized allergic rhinitis
Association of Antenatal Corticosteroid Treatment with Risk of Allergic Diseases in Children
Effect of Metformin on allergen specific immunotherapy
Epicutaneous Allergen Administration with Microneedles as a Novel Method of Immunotherapy for House Dust Mite (HDM) Allergic Rhinitis
Evaluation of Sublingual Immunotherapy for Cat Allergy: Results from a Non-Interventional Study
Immunological evaluation of cat allergic individuals living with or without a cat
Improved quality of life after PQ Grass in comparison to SLIT products in grass allergic patients
Patient survey to determine the minimal clinically important difference for a combined symptom and medication score in grass AIT
Subcutaneous allergen-specific immunotherapies for inhalation allergens induce higher levels of therapy specific IgG4 antibodies than sublingual therapies: a retrospective data analysis
Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions
Systemic reactions to subcutaneous immunotherapy in children
TAPAS – non-inferiority of clinical effectiveness in children compared to adults: interim results of a long-term NIS
The Efficacy of Sublingual Immunotherapy in Mild versus Moderate Atopic Dermatitis Among Children with House Dust Mite Allergic Rhinitis
The individual benefit of subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is already evident in the first season immediately after treatment
The placebo effect leads to significantly lower values regarding allergic symptoms and medication use in birch-pollen allergic patients during the birch pollen season
